Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting
/in Dendritic Cells, International PublicationsAmpligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer
/in Dendritic Cells, International PublicationsAntitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses
/in Dendritic Cells, International Publications, Newcastle Disease VirusHeat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway
/in Dendritic Cells, International PublicationsDendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma
/in Dendritic Cells, International Publications, Multiple MyelomaPhysiological role of plasmacytoid dendritic cells and their potential use in cancer immunity
/in Dendritic Cells, International PublicationsTh-1 polarization is regulated by dendritic-cell comparison of MHC class I and class II antigens
/in Dendritic Cells, International PublicationsImmunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination
/in Dendritic Cells, International Publications, Malignant Melanoma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer